Innate Pharma S.A.
IPHYF
$1.45
-$0.31-17.61%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -1,525.37% | -1,559.15% | 84.81% | 84.42% | -72.14% |
| Total Depreciation and Amortization | -69.02% | -68.28% | -35.84% | -34.24% | 83.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -96.46% | -96.37% | -99.24% | -99.22% | -54.95% |
| Change in Net Operating Assets | 241.93% | 245.30% | -835.74% | -859.31% | -72.53% |
| Cash from Operations | 126.19% | 126.81% | -9.09% | -11.84% | -1,062.04% |
| Capital Expenditure | 9.45% | 7.30% | 61.56% | 60.45% | 24.81% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1,806.41% | 1,851.18% | 816.74% | 839.86% | 157.89% |
| Cash from Investing | 474.61% | 483.55% | 868.20% | 892.53% | 36.36% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -177.29% | -177.29% | 28.18% | 28.18% | -66.39% |
| Issuance of Common Stock | -73.28% | -73.28% | 683.33% | 683.33% | 81.25% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -243.42% | -251.55% | 12.58% | 10.40% | -32.65% |
| Foreign Exchange rate Adjustments | -275.29% | -279.31% | -43.85% | -42.41% | 122.11% |
| Miscellaneous Cash Flow Adjustments | 0.00% | 0.00% | -150.00% | -150.00% | -- |
| Net Change in Cash | 95.25% | 95.14% | 95.45% | 95.34% | -1,522.24% |